Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Our previous study showed that TRIM could
2022-12-13

Our previous study showed that TRIM31 could target TSC1-TSC2 complex and contributed to the clinical cancer progression [6]. In this study, we showed that TRIM31 could directly target p53 for ubiquitous degradation and further mediated anoikis-resistance of HCC cells. To further clarify the role of
-
There are two ways to transport FFAs
2022-12-13

There are two ways to transport FFAs into cells. First by passive diffusion. Second as the putative long-chain fatty Z-YVAD-FMK synthesis transporters are proposed, CD36 the plasma membrane-associated fatty acid-binding protein (FABPpm) and fatty acid transport proteins (FATP) [11], where CD36 is r
-
Several studies have recently used
2022-12-12

Several studies have recently used optogenetics to selectively activate various cholinergic neurons (Jiang et al., 2014). However, most do not explicitly report direct release of GABA from cholinergic fibers, with the exception of our two studies described above (Saunders et al., 2015a, Saunders et
-
br In our experience br History of ER and ACh
2022-12-12

In our experience History of ER and ACh tests As shown in Table 1, Stein et al. first reported the usefulness of intravenous injection of ER in diagnosing coronary insufficiency in 1949 [16]. In 1972, the first ER spasm provocation test was employed at the Cleveland Clinic during cardiac cathe
-
Introduction The lysosomal storage disorder Gaucher disease
2022-12-12

Introduction The lysosomal storage disorder Gaucher disease (Mendelian Inheritance in Man, OMIM #230800) results from the recessively inherited deficiency of lysosomal glucocerebrosidase (GCase, EC 3.2.1.45), caused by mutations in the gene GBA1 (MIM# 606463) located on chromosome 1q21. The enzymat
-
Preliminary results of studies sponsored by the manufacturer
2022-12-12

Preliminary results of studies sponsored by the manufacturer of ETC-1002 have also shown positive results for monotherapy in statin-intolerant patients and for the combined use of the ACL inhibitor plus other cholesterol-reducing agents. In patients with a documented history of intolerance to statin
-
On the other hand there
2022-12-12

On the other hand, there were only a few cases that expressed DA2R in our study. Additionally, in the cases whose ACTH-secreting pituitary adenomas expressed DA2R, the ratio of positive staining SNS-032 was very low. This suggests that dopamine agonists may be less effective in canine Cushing's dis
-
Although the earlier studies focused on
2022-12-12

Although the earlier studies focused on the antioxidant capacity of tocopherols, ascorbic prostaglandin receptor and carotenoids, then it was noticed that phenolic compounds were more powerful than others (Rice-Evans, Miller, & Paganga, 1996). Phenolic compounds, the most numerous and ubiquitous gr
-
br Eprosartan The AT R antagonist eprosartan is approved
2022-12-12

Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential NPE-caged-proton and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular event
-
Recently the FDA approved the first blood
2022-12-12

Recently, the FDA approved the first blood-based test for the detection of EGFR mutations in non-small cell lung cancer patients (http://www.fda.gov) (Voelker, 2016). This allows detection of specific, recurrent mutations, which can help the selection of the patients that could benefit from Erlotini
-
Structural and functional imaging studies searching for spec
2022-12-12

Structural and functional imaging studies searching for specific cortical areas related to each cognitive function domain have provided clues to the spreading patterns of cognitive dysfunction (Domoto-Reilly et al., 2012, Firbank et al., 2016, Li et al., 2012, Machulda et al., 2003, Mandal et al., 2
-
br Introduction AMP activated protein kinase
2022-12-12

Introduction AMP-activated protein kinase (AMPK) has been found to be a key character against cardiovascular diseases and cellular stress. When activated by certain stress, AMPK regulates sugars and fatty acids that are good or detrimental to the heart. For example, targeting AMPK phosphorylatio
-
Previous studies have demonstrated that synaptic AMPARs can
2022-12-12

Previous studies have demonstrated that synaptic AMPARs can differ greatly in their mobility; some rapidly and constitutively TCS 2002 in and out of the synaptic membrane, while others remain somewhat stable in the synaptic membrane (Luscher et al., 1999, Luthi et al., 1999). We find that mGluR- an
-
br Regulation of BCAA catabolism
2022-12-12

Regulation of BCAA catabolism The BCAA catabolic system is equipped in mammalian cells to dispose of excess BCAAs, presumably resulting in relatively stable concentrations of BCAAs in blood and tissues in humans. The main BCAA catabolic pathway is localized in the mitochondria of all tissues. The
-
br Materials and methods br Results br Discussion Several ma
2022-12-12

Materials and methods Results Discussion Several major signaling and developmental pathways (e.g. EGFR, ALK, KRAS, TGFβ, Notch and Wnt/β-catenin) have been shown to be involved in lung carcinogenesis and they are being exploited as targets of the non-small cell lung cancer therapy (for revi
16024 records 361/1069 page Previous Next First page 上5页 361362363364365 下5页 Last page